The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Shockwave Medical
Consulting or Advisory Role - AstraZeneca; Kite, a Gilead Company; Sanofi
Speakers' Bureau - Bristol-Myers Squibb
Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.
 
Konstantin Dragnev
Research Funding - Amgen (Inst); Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Molecular Templates (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Yonina Murciano-Goroff
Employment - Memorial Sloan Kettering Cancer Center (MSK has institutional financial interests relative to Elucida Oncology); Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Consulting or Advisory Role - Abbvie; Revolution Medicines
Research Funding - Abbvie (Inst); Andrew Sabin Family Foundation; Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); Mirati Therapeutics (Inst); National Cancer Institute; National Cancer Institute; National Institutes of Health (NIH)/National Cancer Institute (NCI); Squeri Grant for Drug Development; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca; Loxo Oncology/ Eli Lilly
Other Relationship - Endeavor Biomedicines
 
Natraj Ammakkanavar
No Relationships to Disclose
 
Shinji Takeuchi
Speakers' Bureau - Eli Lilly, Guardant Health Japan. Chugai Pharmaceutical
Research Funding - Eli Lilly, Amgen, Chugai Pharmaceutical
 
Yutaka Fujiwara
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Johnson and Johnson; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; Nippon Kayaku; Ono Pharmaceutical; Otsuka
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novocure (Inst); Shanghai Junshi BioSciences (Inst); Taiho Pharmaceutical (Inst)
 
Timothy Burns
Consulting or Advisory Role - Abbvie/Stemcentrx, Blueprint medicines, Novartis, Thermo Fisher Scientific
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Adrian Sacher
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridgebio (Inst); CRISPR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech/Roche; Merck
(OPTIONAL) Uncompensated Relationships - Amgen; Genentech/Roche; Merck
 
Joanne Lundy
No Relationships to Disclose
 
Takafumi Koyama
Honoraria - AstraZeneca; Chugai Pharma; Sysmex
Consulting or Advisory Role - Amgen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo RD Novare (Inst); Janssen (Inst); Lilly (Inst); Novartis (Inst); PACT Pharma (Inst); Pfizer (Inst); Takeda (Inst); Zymeworks (Inst)
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Loxo; Merck; MERCK (I); Novartis; Pfizer; Pfizer; Quanta Therapeutics; Scorpion Therapeutics; Seagen; Silverback Therapeutics
Speakers' Bureau - Merck
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); BioTheryX (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Loxo@Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); MOMA Therapeutics (Inst); Nektar (Inst); Olema Oncology (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Garrett Sherwood
Employment - Novant Health
Leadership - Novant Health
Stock and Other Ownership Interests - Milestone Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca, Bristol Myers Squibb, Pfizer, Tempus Labs
Speakers' Bureau - AstraZeneca, Bristol Myers Squibb, Pfizer, Tempus Labs
 
Cesar Perez
Consulting or Advisory Role - BeiGene; EMD Serono; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Elpiscience (Inst); Genentech (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merus (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Aaron Fink
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Aaron Chen
Employment - Loxo/Lilly; Sumitomo Pharma Oncology
Stock and Other Ownership Interests - Loxo/Lilly
Travel, Accommodations, Expenses - Loxo/Lilly
 
Geoff Oxnard
Employment - Foundation Medicine; LOXO at Lilly
Stock and Other Ownership Interests - Lilly; Roche
 
Melinda Willard
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Nimit Singhal
Travel, Accommodations, Expenses - Bristol-Myers Squibb